Maxvax Biotechnology, a Chinese developer of innovative vaccines and immunotherapies targeting infectious diseases and cancer, has closed an IDG Capital-led extension round, bringing its total Series C financing to over 600 million yuan ($82.5 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
